# aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-third-quarter-2025-results-and-provides-corporate-update
Ticker: ATYR
Company: aTyr Pharma
Source: aTyr Pharma
Published: 2025-11-06 21:01 EST
Original Source URL: https://investors.atyrpharma.com
## Summary

Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.  Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of

## Article Body
Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.  Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of
## Recent Company News
- 2026-05-15 12:00 EST — [aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-first-quarter-2026-results-and-provides-corporate-update) — Source: aTyr Pharma
- 2026-05-13 20:01 EST — [aTyr Pharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ATYR/atyr-pharma-to-participate-in-upcoming-investor-conferences) — Source: aTyr Pharma
- 2026-05-11 20:01 EST — [aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting](https://biopharmsignal.com/news/ATYR/atyr-pharma-provides-regulatory-and-clinical-update-for-efzofitimod-in-pulmonary-sarcoidosis-following-fda-type-c-meeting) — Source: aTyr Pharma
- 2026-03-05 21:01 EST — [aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update) — Source: aTyr Pharma
- 2026-02-20 21:01 EST — [aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: aTyr Pharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)